A099430 Stock Overview
BioPlus Co., Ltd. engages in the research and development, production, and sale of bio products in South Korea.
BioPlus Co., Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩31,300.00|
|52 Week High||₩43,000.00|
|52 Week Low||₩20,350.00|
|1 Month Change||5.57%|
|3 Month Change||28.81%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-3.54%|
Recent News & Updates
|A099430||KR Medical Equipment||KR Market|
Return vs Industry: Insufficient data to determine how A099430 performed against the KR Medical Equipment industry.
Return vs Market: Insufficient data to determine how A099430 performed against the KR Market.
|A099430 Average Weekly Movement||8.1%|
|Medical Equipment Industry Average Movement||6.7%|
|Market Average Movement||6.5%|
|10% most volatile stocks in KR Market||11.0%|
|10% least volatile stocks in KR Market||4.0%|
Stable Share Price: A099430 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: A099430's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
BioPlus Co., Ltd. engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms.
BioPlus Co., Ltd. Fundamentals Summary
|A099430 fundamental statistics|
Is A099430 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A099430 income statement (TTM)|
|Cost of Revenue||₩15.50b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||800.36|
|Net Profit Margin||27.75%|
How did A099430 perform over the long term?See historical performance and comparison